Jia Liu – CEO, DreamCIS, South Korea
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
Address: 1010, 10F, Jeokseon Hyundai Bld, 80, Jeokseon-dong, Seoul, Jongno-gu, Seoul,Republic of Korea
Tel: +82 2 2010 4500
DreamCIS is a full service contract research organization (CRO) that offers to the pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. DreamCIS provides clinical trial services for a broad and detailed range of therapeutic area in accordance with the standard operating procedures consistent with both Republic of Korean regulations and global standards including ICH-GCP guidelines. DreamCIS aims at enhancing both the reliability of its clinical services provided and product competitiveness by striving to maintain the consistency in quality of its services. Accomplishing this goal will no doubt enable us to contribute to the health of the people. DreamCIS has its Specialist Advisory Committee comprised of high-level specialists in their field to provide comprehensive and specialized clinical services. The community in partnership with DreamCIS include Ionet Republic of Korea which was organized by DreamCIS exclusively for the development of Web-CRF program, DreamCIS’s patented product, Yonsei University Department of Biostatics Medical College, YOU & ME Patent and Law Firm, Yonsei University Research Institute of Food & Nutrition, SMSI (Seoul Medical Science Institute), Biotoxtech Co.,Ltd. DreamCIS has launched a business partnership with Gleneagles CRC (Singapore), a leading CRO/SMO in the Asia Pacific region, with the aim to conduct multi-national clinical trials seamlessly for multi-national customers as well. Founded in April, 2000, DreamCIS has ever since been dedicated to providing a full range of clinical services for a number of customers/sponsors, including major pharmaceutical companies, multi-national pharmaceutical companies, bio venture companies, health food producers, and medical device manufacturers in Republic of Korea. DreamCIS will continue striving to provide customers reliable clinical trial data while conducting all of clinical trials using our expertise and significant experience in the field of clinical trials.
It aims to provide customers differentiated services based on strict quality control in a scientific and systematic manner and high ethical standards. DreamCIS’ key service areas include: ㆍClinical trials for medicines / medical devices ㆍPost-marketing surveillance (PMS) ㆍQA audit ㆍData management and Statistical analysis ㆍHealth functional foods Trials ㆍPre-clinical trials management ㆍTraining and dispatch of clinical research nurses
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
See our Cookie Privacy Policy Here
